Publications by authors named "H Baccouche"
Article Synopsis
- - The patient is a 58-year-old with a history of stage III-A IgG Kappa multiple myeloma, diagnosed in 2016, who experienced a relapse in 2022 and subsequently developed a large spontaneous hematoma requiring surgery.
- - He presented normal platelet counts and hemostasis but was diagnosed with acquired factor XIII deficiency and thrombopathy, creating diagnostic challenges due to the lack of specific tests for the Factor XIII B subunit.
- - Despite treatments like transfusions and corticosteroids, the effectiveness was limited, and factors fluctuated without symptoms, ultimately making the patient ineligible for autograft due to the risk of hemorrhage.
Article Synopsis
- Platelet count is essential for clinical decisions, but the impedance technique (PLT-I) may overestimate counts in cases of microcytosis, prompting a comparison with the optical technique (PLT-O).
- A study analyzed blood samples with microcytosis (MCV<80 fL) and found a strong correlation between PLT-I and PLT-O for platelet values below 150 x 10^9/L, though a bias of 16.53 x 10^9/L was noted.
- The research suggests that while impedance can be used routinely, the optical technique should be used for samples with MCV<72.9 fL or when schizocytes are present to ensure accurate hemogram validation.
Background: Over the past decades, thrombophilia testing in patients with venous thrombo-embolism has increased tremendously. However, the role of inherited thrombophilie in prediction the risk of recurrence remains controversial. Consequently, it is still unclear whether thrombophilia testing influences decisions regarding duration of anticoagulation in clinical practices.
View Article and Find Full Text PDFArticle Synopsis
- - This study investigates the effectiveness of different aspirin dosing regimens in diabetic patients who suffered from non-ST elevation acute coronary syndrome (NSTE-ACS) by measuring the body's ability to generate thrombin.
- - A total of 59 diabetic patients were randomly assigned to one of three treatment groups: 100 mg once daily, 160 mg once daily, or 100 mg twice daily, with outcomes assessed at discharge and six months later.
- - Results indicated that while the once-daily aspirin doses had no significant impact on thrombin generation over time, the twice-daily regimen significantly reduced thrombin levels, suggesting better management of hypercoagulability in these patients.
Background: Multiple myeloma is a hematologic malignancy which confers a high venous thromboembolic risk. This risk is linked to patient-related factors, disease-specific mechanisms, and antimyeloma therapy, especially immunomodulatory drugs. Some studies have suggested that the thrombin generation assay may be a predictive marker of thrombosis.
View Article and Find Full Text PDF